ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

Study details: Fu et al. 2016

This observational cohort study used a U.S. insurance claims database to compare the risk of hospitalisation for heart failure (hHF) between patients with type 2 diabetes mellitus treated with DPP-4i vs. SU and between those treated with saxagliptin vs. sitagliptin.

Secondary analyses compared the aforementioned groups with respect to other CV outcomes: risk of hospitalisation for acute myocardial infarction (AMI), hospitalisation for stroke, hospitalisation for unstable angina, coronary revascularisation, and a composite of all outcomes together, including hHF.

Methods followed the FDAs Mini-Sentinel protocol for active surveillance of antidiabetic agents.

Patients initiated treatment between 8/1/2010 and 8/30/2013 and had no use of the comparator treatments in the prior 12 months (baseline). Each comparison consisted of patients matched 1:1 on a propensity score (nearest neighbour; caliper=0.01). Analyses were stratified by presence of baseline CVD. Time to hHF was compared between matched groups using Cox models. 

 

Veeva code: GB-7993

Date of preparation: August 2017